RNA polymerase variants
By modifying the amino acid sequence of T7 RNA polymerase, a high sequence-uniform RNA polymerase variant was developed, solving the problem of low utilization of cap analogs and achieving high mRNA product capping rate and cost savings.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NANJING VAZYME BIOTECH CO LTD
- Filing Date
- 2025-04-02
- Publication Date
- 2026-07-17
AI Technical Summary
In the in vitro transcription process, existing RNA polymerases have low utilization rates of cap analogs, requiring the replacement of wild-type promoters, which leads to increased production costs and potential safety issues. Furthermore, RNA products that fail to be capped require column purification.
By modifying the amino acid sequence of T7 RNA polymerase, especially by introducing mutations at the K387, D388, or K389 positions, RNA polymerase variants with high sequence consistency can be developed, improving the utilization rate of cap analogs and avoiding promoter substitution.
It improved the utilization rate of cap analogues, reduced raw material waste, lowered production costs, and increased the capping rate and integrity of mRNA products.
Smart Images
Figure CN122405587A_ABST